Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study. (Record no. 19170075)

MARC details
000 -LEADER
fixed length control field 01622 a2200481 4500
005 - DATE AND TIME OF LATEST TRANSACTION
control field 20250515185908.0
008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION
fixed length control field 200912s 0 0 eng d
022 ## - INTERNATIONAL STANDARD SERIAL NUMBER
International Standard Serial Number 1095-6859
024 7# - OTHER STANDARD IDENTIFIER
Standard number or code 10.1016/j.ygyno.2009.08.024
Source of number or code doi
040 ## - CATALOGING SOURCE
Original cataloging agency NLM
Language of cataloging eng
Transcribing agency NLM
100 1# - MAIN ENTRY--PERSONAL NAME
Personal name Joly, F
264 #0 - PRODUCTION, PUBLICATION, DISTRIBUTION, MANUFACTURE, AND COPYRIGHT NOTICE
Date of production, publication, distribution, manufacture, or copyright notice 20091201
245 00 - TITLE STATEMENT
Title Weekly combination of topotecan and gemcitabine in early recurrent ovarian cancer patients: a French multicenter phase II study.
Medium [electronic resource]
260 ## - PUBLICATION, DISTRIBUTION, ETC.
Name of publisher, distributor, etc. Gynecologic oncology
Date of publication, distribution, etc. Dec 2009
300 ## - PHYSICAL DESCRIPTION
Extent 382-8 p.
Other physical details digital
500 ## - GENERAL NOTE
General note Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Adult
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aged
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Aged, 80 and over
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Antineoplastic Combined Chemotherapy Protocols
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Deoxycytidine
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Drug Administration Schedule
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Female
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Humans
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Infusions, Intravenous
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Middle Aged
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Ovarian Neoplasms
General subdivision drug therapy
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Quality of Life
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Topotecan
General subdivision administration & dosage
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Treatment Outcome
650 04 - SUBJECT ADDED ENTRY--TOPICAL TERM
Topical term or geographic name entry element Gemcitabine
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Petit, T
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Pautier, P
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Guardiola, E
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Mayer, F
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Chevalier-Place, A
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Delva, R
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Sevin, E
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Henry-Amar, M
700 1# - ADDED ENTRY--PERSONAL NAME
Personal name Bourgeois, H
773 0# - HOST ITEM ENTRY
Title Gynecologic oncology
Related parts vol. 115
-- no. 3
-- p. 382-8
856 40 - ELECTRONIC LOCATION AND ACCESS
Uniform Resource Identifier <a href="https://doi.org/10.1016/j.ygyno.2009.08.024">https://doi.org/10.1016/j.ygyno.2009.08.024</a>
Public note Available from publisher's website

No items available.